Objective To investigate the clinical curative effects and safety of blood purification combined with Compound α-Ketonic Acid in the treatment of uremia. Methods 80 patients with uremia treated in our hospital from June 2010 to September 2011 were randomly divided into the control group and the treatment group, with 40 patients in each group. The control group was given the blood purification and the other conventional treatment, and the treatment group was given the oral administration of Compound α-Ketonic Acid for one year on the basis of the control group. The blood urea nitrogen (BUN), creatinine (Cr), serum parathyroid hormone (PTH) and serum β2-microglobulin (β2-MG) value changes, the clinical curative effects and the incidence of adverse reactions of the two groups were compared before and after treatment. Results One year after treatment, the BUN, Cr, β2-MG and PTH levels of both groups of patients were significantly reduced (P < 0.05), and the reduction degrees of β2-MG and PTH of the treatment group were significantly lower than those of the control group (P < 0.05); The obvious effective rate and the total effective rate of the treatment group were significantly higher than those of the control group (P < 0.05); the incidence of adverse reactions of the two groups was not significantly different (P > 0.05). Conclusion Blood purification combined with Compound α-Ketonic Acid can effectively improve the situation of uremia and has exact clinical curative effects and few side effects, thereby worthy of promotion and application.%目的 探讨血液净化联合复方α-酮酸治疗尿毒症的临床疗效以及安全性.方法 将我院2010年6月~2011年9月收治的80例尿毒症患者随机分为对照组与治疗组,每组各40例,对照组给予血液净化等常规治疗,治疗组在对照组基础上给予复方α-酮酸治疗口服1年.比较两组治疗前后的血尿素氮(BUN)、肌酐(Cr)、血清甲状旁腺素(PTH)、血清β2-微球蛋白(β2-MG)值的变化、临床疗效以及不良反应发生率.结果 两组病人治疗1年后BUN、Cr、β2-MG、PTH水平显著降低(P ＜ 0.05),且治疗组β2-MG、PTH降低程度显著大于对照组(P ＜ 0.05);治疗组显效率和总有效率均明显高于对照组(P < 0.05);两组不良反应的发生率比较差异无统计学意义(P > 0.05).结论 血液净化联合复方α-酮酸能够有效的改善尿毒症状况,临床疗效确切,不良反应小,值得推广应用.
展开▼
